Point-of-care measurements reveal release of purines into venous blood of stroke patients by Dale, N et al.
ORIGINAL ARTICLE
Point-of-care measurements reveal release of purines
into venous blood of stroke patients
Nicholas Dale1,2 & Faming Tian2 & Ravjit Sagoo3 & Norman Phillips4 & Chris Imray3,5 & Christine Roffe6
Received: 26 October 2018 /Accepted: 31 January 2019
# The Author(s) 2019
Abstract
Stroke is a leading cause of death and disability. Here, we examine whether point-of-care measurement of the purines, adenosine,
inosine and hypoxanthine, which are downstream metabolites of ATP, has potential to assist the diagnosis of stroke. In a
prospective observational study, patients who were suspected of having had a stroke, within 4.5 h of symptom onset and still
displaying focal neurological symptoms at admission, were recruited. Clinical research staff in the Emergency Departments of
two hospitals used a prototype biosensor array, SMARTCap, to measure the purines in the venous blood of stroke patients and
healthy controls. In controls, the baseline purines were 7.1 ± (SD) 4.2 μM (n = 52), while in stroke patients, they were 11.6 ±
8.9 μM (n = 76). Using the National Institutes for Stoke Scale (NIHSS) to band the severity of stroke, we found that minor,
moderate and severe strokes all gave significant elevation of blood purines above the controls. The purine levels fall over 24 h.
This was most marked for patients with haemorrhagic strokes (5.1 ± 3.6 μM, n = 9 after 24 h). The purine levels measured on
admission show a significant correlation with the volume of affected brain tissue determined by medical imaging in patients who
had not received thrombolysis or mechanical thrombectomy.
ClinicalTrials.gov Identifier: NCT02308605
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Introduction
Throughout the world, stroke is one of the leading causes of
death and disability [1–3]. In the USA, there are approximate-
ly 795,000 strokes per year, and it is estimated that someone
has a stroke every 40 s [3]. About 87% of these strokes are
ischaemic, 10% caused by intracerebral haemorrhage and 3%
by subarachnoid haemorrhage [3]. For patients suffering an
ischaemic stroke, thrombolytic treatment can greatly improve
outcome. However, speed is of the essence as during an isch-
aemic stroke as brain tissue is lost at an alarmingly rapid rate;
for example, the brain has been estimated to prematurely age
by 3.1 weeks for every minute of an untreated stroke [4].
Rapid lysis of thrombi by administration of alteplase signifi-
cantly improves recovery [5]. A detailed study has estimated
that for every 15-min reduction of delays in provision of treat-
ment, there is on average a gain of one extra month of
disability-free life [6].
Evaluation of how quickly stroke units provide thrombo-
lytic treatment after arrival at hospital suggests that although
many centres around the world achieve delays of < 30 min,
typical routine practice still leaves room for substantial im-
provement [6]. Furthermore, given the rate of loss of brain
matter and the benefit of early thrombolysis, Bfine-tuning of
even the best of services is beneficial^ [6].
Current thinking suggests that improving the door to needle
time (DNT) for thrombolysis requires Bcontinuous analysis
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and stepwise improvement of the system as a whole^ [6].
Early recognition and diagnosis of a stroke is clearly a vital
component for achieving rapid DNTs. While diagnosis of
stroke will always require clinical examination and judge-
ment, this process can be assisted and potentially sped up by
analytical technologies. Use of proteomic biomarker panels
has shown how, albeit imperfect, analytical tools can be inte-
grated with other clinical data to assist in the early diagnosis
and management of stroke patients [7, 8].
In this study, we examine whether point-of-care purine
measurements have potential to assist in the diagnosis of
stroke. The purines adenosine, inosine and hypoxanthine are
downstream metabolites of ATP. In tissue that is under meta-
bolic stress, e.g. during hypoxia or ischaemia, the intracellular
ATP-pool breaks down to adenosine and downstream metab-
olites. These purines are released from cells via transporters
and are thus a very early marker of metabolic stress that occurs
prior to cell death [9–20]. Using the cross-clamp phase of
carotid endarterectomy as a model of diffuse brain hypoxia/
ischaemia, adenosine measured in blood has been shown to be
a very sensitive marker of brain ischaemia [21].
Purine measurements have not been widely used in clinical
research because they are technically difficult and labour-
intensive to achieve. Once blood has been drawn from the
patient, the purines are subject to a number of degradative
and uptake processes that cause their half-life in blood to be
very short (minutes). This necessitates complex pretreatment
of blood samples as soon as they are obtained to remove the
cells and inactivate degradative processes to try and preserve
the purine content of the sample. These methods are complex
and prone to variation, and not suited to widespread applica-
tion in a clinical setting. A point-of-care system for measure-
ment of purines in unprocessed blood would obviate these
complications and usher in a new era where measurement of
the purines could be a new analytical tool for clinicians. We
invented electrochemical biosensors for adenosine and down-
stream purines initially as a lab tool [22–24]. We have now
developed these biosensors into a very early prototype biosen-
sor array, SMARTCap, which is capable of measuring purines
in fresh unprocessed blood. In this study, clinical research staff
used SMARTCap in the Emergency Departments of two hos-
pitals to investigate whether the purines are elevated in the
blood of stroke patients compared to healthy controls.
Materials and methods
Ethics
This trial was approved by the Regional Coventry and
Warwickshire Research Ethics Committee (14/WM/1067) on
19th August 2014. It is registered as NCT02308605.
Trial design
This was a prospective observational study of purine levels in
patients admitted with a clinical diagnosis of acute stroke.
Participants
Patients were recruited from the emergency departments of
two large tertiary care hospitals (the University Hospital of
Coventry and Warwick NHS Trust and the University
Hospital of North Midlands NHS Trust) between 30
September 2014 and 10 July 2015 if they had a clinical diag-
nosis of suspected acute stroke e.g. Face Arm Speech Test
(FAST) positive [25] or other relevant clinical signs [26], were
within 4.5 h of symptom onset, and were still displaying focal
neurological symptoms at the time of assessment. All partic-
ipants entered the normal clinical care pathway for stroke at
the respective hospital (Fig. 1).
Controls
Healthy individuals of similar age were recruited as controls
(Fig. 1). These were the relatives and friends of stroke patients
recruited to the study. A brief questionnaire was given to ex-
clude comorbid conditions and medications which might af-
fect purine levels and to ensure that none of the healthy con-
trols had been diagnosed as having vascular disease.
Consent
As this was a trial in an emergency setting and informed con-
sent would have delayed time critical investigations and treat-
ment, we used a model of deferred consent. The first blood
sample was taken as soon as possible after arrival in hospital,
usually together with the routine emergency bloods. Fully
informed consent was obtained from the patient, or, if the
patient was incompetent to give consent, a legal representative
as soon as practicable after emergency treatment and, before
the next study-related activity (the 24-h blood sample). If con-
sent could not be gained or was refused, no further trial pro-
cedures were undertaken and the result of the purine test con-
ducted before consent and the data removed from the study
(Fig. 1). Fully informed consent was obtained from all healthy
individuals recruited as controls before commencement of any
trial-related procedures.
Blood sampling
As soon as possible after admission, blood from a
consented patient (or a patient where retrospective consent
was being sought) was drawn into a vacutainer and the
SMARTCap device was used to measure purines in this
sample. This first measurement was considered to be the
Purinergic Signalling
admission or B0-h^ measurement. Twenty-four hours later,
the procedure was repeated.
SMARTCap
The SMARTCap consisted of an array of four working elec-
trodes and two Ag/AgCl pseudoreference electrodes (Fig. 2a).
The working electrodes were gold and coated with ruthenium
purple, which acts as a surface-bound mediator to create high-
ly selective biosensors [24]. Two of the working electrodes
were coated with the enzyme cascade required for purine de-
tection (Fig. 2b), while the remaining two were coated with a
layer that lacked the enzymes.
SMARTCap was used to make chronoamperometric re-
cordings of the working electrodes at a potential of − 50 mV
versus the Ag/AgCl reference electrode. When introduced
into blood, the SMARTCap was polarised to its working po-
tential of − 50mV for 3 min. At the end of this period, the data
values from the final 10 s of the recording were averaged for
each working electrode. The purine biosensors are sensitive to
adenosine, inosine, hypoxanthine and xanthine. The null sen-
sors lack sensitivity to these compounds and act as a control
for any non-specific interferences and also to set the Bzero
current^ level for the absence of purines from the measure-
ment sample. All measurements are thus performed as the
difference between the two biosensor and two null electrodes
giving a total of four measurements from one sample. These
were averaged to give a single value.
The SMARTCap was designed to fit into a vacutainer to
enable measurement of purines in fresh unprocessed blood.
Prior to taking the blood sample, the SMARTCap was
rehydrated and calibrated against a known concentration of
Fig. 2 Design and operational principles of SMARTCap. a Diagram of
SMARTCap showing the four working electrodes (black) and two Ag/
AgCl pseudo-reference electrodes (grey). Two of the working electrodes
were coated with a gel layer containing the enzymes for a purine
biosensor. The other two working electrodes were coated with a gel
layer lacking enzymes to comprise null biosensors). b Enzymatic
cascade used on the working electrodes for detection of purines
Fig. 1 Consort diagram for the SMARTCap trial. Purine measurements
on admission and at 24 h were not obtained because the measurement
procedure ran into a problem and one of the steps could not be completed;
or the measurement was completed but the resulting electrochemical data
was spurious (see BMaterials and methods^); or, for the 24-h purine level,
the patient was repatriated before the measurement could be made.
Twenty-four- to 48-h scans were not made because the MR scanner was
not available; or the patient did not consent for anMR scan; or the patient
was too ill for the MR scan; or the patient was repatriated before the scan
could be made
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adenosine. Once the blood was drawn into a vacutainer from
the patient, the SMARTCap was introduced to the sample as
quickly as possible and the measurement made.
The potentiostat that controlled the SMARTCap was driv-
en by bespoke software, which gave instructions to the user at
each stage and stored the electrochemical data. The purine
measurement itself and data were not revealed to the nurses.
Some quality checks were built into the software to check for
faulty SMARTCaps, or faults in use. The nurses were notified
if a measurement was successful or had failed.
Validity of electrochemical data
The electrodes in SMARTCap follow well-understood elec-
trochemical behaviour and exhibit faradaic charging curves
when polarised to the working potential which start from a
negative current and decay to a current value close to zero
[24]. These charging curves were stored for subsequent in-
spection. For apparently successful measurements, i.e. they
had passed the initial quality checks in the software, the re-
cordings from any electrodes that did not exhibit the expected
curves were rejected. Given the redundancy within
SMARTCap (two nulls and two working electrodes), the cal-
culation to determine the concentration of purines was per-
formed with all valid charging curves. In the event that all of
the charging curves were found to be invalid for a
SMARTCap measurement, this was recorded as a failed mea-
surement. For stroke patients, 24 measurements of purines on
admission and 18 measurements at 24 h failed according to
these criteria. For control patients, 21 measurements failed.
Clinical assessments of patients
Demographic data, comorbidities, medications and the
neurological status e.g. National Institutes for Health
Stroke Scale (NIHSS) [27] were recorded at baseline. A
purine measurement was taken as soon as possible after
admission either before or immediately after the baseline
computed tomography (CT) head scan that all participants
had on admission as part of standard clinical care. The
purine measurements were performed before any reperfu-
sion treatment such as thrombolysis or thrombectomy had
been commenced. At 24 h after enrolment, a second purine
measurement was taken in participants who had given fully
informed consent. Magnetic resonance imaging (MRI) of
the head was conducted in consented participants within
24–48 h after enrolment to obtain imaging evidence to
confirm the clinical diagnosis and give an estimate of the
volume of affected brain tissue. In participants who had
contraindications to MRI or were unable to tolerate the
procedure, a CT scan was performed instead of the MRI.
Image analysis and calculation of brain volume
A radiologist blinded to the patient’s details, presentation and
purine measurements performed the image analysis. Brain CT
scans undertaken at presentation and follow-up CT/MR scans
undertaken at 24–48 h were imported into and analysed using
OsiriX software (Pixmeo, Geneva, Switzerland). CT scans were
performed unenhanced. The following brain MR sequences
were utilised:
1. Standard sagittal T1, axial T2 and axial T2 fluid attenuat-
ed inversion recovery (T2-FLAIR)
2. Coronal susceptibility weighted imaging (SWI) to aid in
identifying micro haemorrhages
3. Axial diffusion weighted imaging (DWI) with associated
apparent diffusion coefficient (ADC) maps to confirm the
presence of an acute infarction
A data collection sheet based on the Acute Ischaemic Stroke
Classification Template developed by the Edinburgh Brain
Research Imaging Centre was used to record all abnormalities
identified on the CTandMR scans (SBIRCwebsite, www.sbirc.
ed.ac.uk/imageanalysis.html, J Wardlaw) [28, 29]. A diagnosis
of acute infarction was made on MR if there was evidence of
restricted diffusion on DWI/ADC as well as appropriate abnor-
malities seen in the remainder of the sequences. Acute infarc-
tions were diagnosed on CT using well-known, classical radio-
logical signs including loss of grey-white matter differentiation
in a cerebral arterial territory (together with mass effect due to
cerebral oedema) and a hyperdense major cerebral artery (usu-
ally the middle cerebral artery). CT scans were also utilised to
assess for intracerebral haemorrhage.
Volumes of acute infarctions and intracerebral haemorrhages
were calculated in OsiriX by manually tracing around the edges
of the regions of interest on the DWI sequence and CT scan,
respectively. This was done on each relevant image slice to
obtain a volume via the in-built volume calculation tool.
Statistical analysis
Inspection of the data showed that the controls, strokes and
mimics appeared to be normally distributed. Therefore, para-
metric tests (ANOVA and unpaired t tests) were used to com-
pare data from different groups. Given the scatter apparent in
the data, correlations between variables were assessedwith the
Spearman rank correlation test. Receiver operating character-
istic (ROC) analysis was performed with the aid of the pROC
package in R.
Funding
This project (II-LA-0313-20002) is funded by the National
Institute for Health Research Invention for Innovation
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Programme. The views and opinions expressed therein are
those of the authors and do not necessarily reflect those of
the Invention for Innovation Programme, the National
Institute for Health Research, the NHS or the Department
of Health.
Results
Purine levels in stroke patients, stroke mimics,
and controls
In healthy control patients, the purines measured in venous
blood had a mean concentration of 7.1 ± (SD) 4.2 μM (n =
52, Fig. 3). In patients with a diagnosis of stroke, the mean
purine concentration was 11.6 ± 8.9 μM (n = 76, Fig. 3). A
small number of patients, initially diagnosed as strokes, were
subsequently determined to be stroke mimics. The purine
levels of these patients had a mean concentration of 6.5 ±
4.7 μM (n = 9) and are also illustrated in Fig. 3, along with
the particular condition. Three further patients were not diag-
nosed as either a stroke or a stroke mimic: One of these suf-
fered from cervical cord compression (admission purines
29.3 μM); one had venous sinus and internal jugular throm-
bosis (admission purines 15.9 μM); and the final patient had
an unclear diagnosis, but myocardial infarction was suspected
(admission purines 24.4 μM).
A three-level single-factor ANOVA suggested that the ad-
mission purine levels in controls, stroke patients and stroke
mimics were significantly different (F2.133 = 6.89, p < 0.01). A
separate post hoc comparison between stroke patients and
controls showed that it was highly unlikely that they were
drawn from the same underlying population (p = 0.0004).
We therefore conclude that purines are elevated in the venous
blood of stroke patients. In our patient sample, there were
examples of both ischaemic and haemorrhagic strokes and
the purine levels were elevated in both groups.
Although the numbers are too small to draw a confident
conclusion, conditions that can be hard to distinguish from
true strokes (functional strokes and seizures) seemed to have
low purine levels (p = 0.047 compared to stroke). Individuals
with TIAs exhibited a range of purine levels, perhaps
reflecting the variability in severity of the TIA (Fig. 3).
Purine levels versus the severity of stroke
As purines are released from cells that are metabolically
stressed or that have died, the concentration of purines mea-
sured in blood might be expected to correlate with the severity
of the stroke and the volume of affected brain tissue. We there-
fore used the baseline NIHSS to group patients into minor,
moderate, severe and very severe strokes (Fig. 4). An analysis
of variance, comparing these four bands along with the controls
showed that the five groups were not drawn from the same
population (F4,117 = 4.7618, p < 0.01). Subsequent post hoc
comparisons showed that the minor, moderate and very severe
stroke groups were all elevated with respect to the control.
Overall, there was a progression that was suggesting that higher
purine levels were associated with more severe strokes, but this
correlation was not statistically significant (Fig. 4).
One possible confounding factor in our study is that the
measurements of purines in blood taken at admission were
performed at differing times relative to the onset of symptoms.
If the purines in blood were to rise slowly, or decay quickly, an
influence of time of sampling on the measured purine level
might be expected. Analysis of all the stroke patients showed
Fig. 3 Purine levels in venous blood of stroke patients are elevated
relative to those measured of healthy controls. Dot plots showing the
values of purines measure with SMARTCap in healthy controls, stroke
patients, and patients identified as stroke mimics. Box plots show mean
and SD, whiskers are 5–95 percentiles. Comparison of three groups with
three-level single factor ANOVA, followed by pairwise t tests
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no correlation between the time from symptom onset and the
level of purines (Rs = 0.171). To examine this further, we
categorised patients via their baseline NIHSS and to test
whether there was any effect of measurement time relative to
symptom onset on the measured purine levels in patients with
strokes of differing severity (Fig. 5). Interestingly, there was a
positive correlation (Rs = 0.54, p = 0.0207, Fig. 5) between
time from stroke onset and venous purine levels for patients
with minor strokes, but a negative correlation for patients with
moderate strokes (Rs = − 0.389, p = 0.03389, Fig. 5). A similar
trend was evident in patients with severe and very severe
strokes; however, the correlation was not significant in these
patients. This may have been due to the small number of
patients in these more severe categories (Fig. 5).
Purine levels versus affected brain volume
We performed medical imaging, either with CT on admission
orMR 24–48 h after admission. This enabled us to test wheth-
er the purine levels measured on admission correlate with the
volume of affected brain tissue evident in the imaging. In
patients with a diagnosis of an ischaemic stroke and who
had been given thrombolysis, no correlation between volume
of affected brain (determined by MR scan) and the purine
measurement was evident (Fig. 6, inset). This is reassuring,
as the purpose of thrombolysis is to rescue the affected tissue.
Although the region of affected brain will be highly stressed
initially and thus release purines, the reperfusion arising from
thrombolysis should prevent a significant proportion of these
stressed cells from dying. Hence, we would expect the throm-
bolytic intervention to break any potential link between the
initial purine levels and volume of affected brain.
We next examined patients who did not receive throm-
bolysis and plotted the initial purine levels in blood versus
the volume of affected brain. A significant correlation
between blood purine levels and volume of affected brain
tissue was evident (p = 0.00314, Fig. 6). This group in-
cluded both ischaemic and haemorrhagic strokes. When
we analysed haemorrhagic strokes on their own, a corre-
lation between purine levels and volume of affected brain
determined by the CT scan on admission was also evident
(p = 0.00455, Fig. 6). There was an insufficient number of
non-thromoblysed ischaemic stroke patients in our dataset
to warrant their separate analysis.
Time course of purine levels over 24 h
In 36 stroke patients, a second purine measurement 24 h after
admission was successfully completed. The mean purine level
was 7.6 ± 6.5 μM. This value was significantly lower than that
recorded on admission (p = 0.01) and was not significantly
different from the control group, suggesting at least a partial
return of purine levels towards those of healthy controls over
the 24-h period.
Further analysis of patients with a definite diagnosis
of either ischaemic or haemorrhagic stroke suggested that
the purine levels for ischaemic and haemorrhagic strokes
recovered at different rates over 24 h (Fig. 7). When
measured on admission, the mean purine level for isch-
aemic and haemorrhagic strokes was 11.0 ± 8.5 μM (n =
37) and 13.8 ± 7.7 μM (n = 11), respectively. After 24 h,
the purine levels had respectively reduced to 8.4 ± 7.1
(n = 26) and 5.1 ± 3.6 μM (n = 9). This was not a signif-
icant change for the ischaemic stroke patients (p =
0.109); however, for the haemorrhagic stroke patients,
this reduction of the purine levels over 24 h was highly
significant (p = 0.0029).
Fig. 4 Purine levels measured in stroke patients grade with severity of
stroke classified byNIHSS. A five-level single factor ANOVA shows that
the purine levels in controls and stroke groups are significantly different.
Pairwise t tests show that purine levels in minor, moderate and very
severe stroke patients are significantly elevated relative to controls. Box
plots show mean and SD, whiskers are 5–95 percentiles
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Discussion
The key findings of our study are that purines are elevated in
the venous blood of stroke patients when compared to healthy
controls and patients with conditions mimicking stroke. This
rise in purines is found irrespective of the underlying cause of
the stroke (infarct or haemorrhage) and can be identified in all
levels of stroke severity. Within 24 h of stroke onset, purine
levels decline and this is more marked in strokes caused by
haemorrhage than in infarcts. In patients who did not receive
thrombolysis, a treatment that has the potential to reverse ce-
rebral ischaemia, there was a strong correlation between pu-
rine levels measured on admission and the volume of affected
brain tissue. Although the sample numbers are low, our data
suggests that the purine levels of at least some stroke mimics
may be lower than those of true strokes. Purine measurements
may have potential in identifying stroke mimics and
distinguishing them from true stroke patients.
To our knowledge, this is the first point-of-care study to
assess purine levels in the blood of stroke patients in
Fig. 5 Purine levels in venous blood of stroke patients plotted against
time from symptom onset, separated according to NIHSS. For minor
strokes (NIHSS 1–4), there is a statistically significant positive
correlation, i.e. the longer the delay in measurement, the higher the
purine level in blood. For moderate strokes (NIHSS 5–15), there is a
slight but statistically significant negative correlation, i.e. with symptom
onset time to measurement delay, there is a slight fall in purine levels.
With strokes of greater severity, a similar trend cannot be excluded, but
the numbers are too small to interpret reliably. RS Spearman’s rank
correlation coefficient
Fig. 6 Purines measured at time of admission correlate with volume of
affected brain tissue measured by CT or MR imaging. The top panel
shows non-thrombolysed ischaemic and haemorrhagic patients; the
bottom panel shows only haemorrhagic patients. The inset shows lack
of correlation between purines measured on admission and infarct size
measured by MRI in ischaemic stroke patients who had undergone
thrombolysis/thrombectomy. CT scans performed the same day as
admission for haemorrhagic patients, one ischemic stroke patient had
CT scan performed at 24–48 h after admission, and the MRI scans
performed 24–48 h after admission. RS Spearman’s rank correlation
coefficient
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comparison to healthy controls. An earlier study [30] exam-
ined adenosine levels in patients who had suffered either TIA
(n = 10) or stroke (n = 10) by lab-based HPLC measurements.
In this study, adenosine levels were claimed to be elevated
above the normal range for several days. However, no age-
matched controls were performed, the absolute levels of aden-
osine recorded were in the 100 s of nM, and the elevation
above the presumed normal range very modest. In our study,
we measured a combination of purines (adenosine, inosine
and hypoxanthine), and consequently the absolute levels re-
corded were much higher, potentially giving a wider dynamic
range for our measurements. By using a point of care in vitro
diagnostic device, we have been able to sample a far larger
number of patients and controls.
In patients with minor strokes as classified by their baseline
NIHSS, there was a positive correlation between the time of
measurement time relative to symptom onset time and the
level of purines in venous blood. This could have been due
to stroke progression. Should future studies confirm this hy-
pothesis, repeated measurements of purine levels over the first
few hours could have clinical utility in monitoring the devel-
opment or resolution of the pathology in patients with strokes.
A limitation of this study is that variability in the measure-
ments is higher than expected based on our previous observa-
tions and that the measured levels of purines in the healthy
controls were some threefold greater than the literature would
suggest. A priori, a level for purines in the low micromolar
range with relatively little variance would be expected in con-
trols. Indeed, in a previous study on patients undergoing ca-
rotid endarterectomy performed by researchers highly skilled
in the use of biosensors (the inventors), the baseline purines
measured in arterial blood were 2.4 ± 1.94 μM [31]. This sug-
gests that systematic measurement/sampling errors may have
affected our study. We think it unlikely that the values reflect a
difference between arterial and venous blood, as recent studies
using a next-generation device (SMARTChip) show very little
difference in purine levels between finger-prick and arterial
blood (O. Fisher, C. Imray, F. Tian, N. Dale unpublished ob-
servations). However, we are aware of three potential sources
of error. Firstly, the SMARTCap was a very early prototype
in vitro diagnostic device that was essentially handmade and
developed specifically to enable this study. There was a high
degree of variability between devices, and variation in their
performance. We can state this with a high degree of certainty,
because each SMARTCap had two purine biosensors and two
null biosensors giving a total of four possible measurements.
If the device were to work perfectly, all four measurements
would be identical. Inspection of the raw data shows that this
was never the case. This measurement variability arises from
slight differences in the integrity of the coatings on the indi-
vidual electrodes and hence their analytical performance. The
final value for the purines was simply the mean of all of the
valid (see BMaterials and methods^) individual measure-
ments. Secondly, SMARTCap, being a very early prototype
device, proved difficult to use in the emergency setting. It took
several training sessions, and experience through use, for the
clinical research staff to attain proficiency in making measure-
ments with SMARTCap. These difficulties resulted in a great-
er number of invalid measurements than originally expected.
Furthermore, difficulties in use of SMARTCap may have led
to delays in making the measurement of the blood samples.
Metabolism, hypoxia-induced release or uptake of the purines
into red blood cells in the ex vivo samples prior to completion
of the measurement could have introduced further variability
into the results. Thirdly, the purine measurements may have
been affected by the method of blood draw. Obtaining the
Fig. 7 Purine levels show a trend
to normalisation 24 h after
admission. The purines measured
at time of admission and at 24 h
shown for ischaemic and
haemorrhagic strokes.
Comparison of 0 h and 24 h via t
tests. The difference is not
significant for ischaemic strokes
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blood via a needle may lead to significant haemolysis and
hence release of purines from damaged erythrocytes. These
limitations affect the measurement of purines in the control
group and the stroke group to the same extent. Despite these
difficulties, use of SMARTCap was sufficient to enable the
collection of the largest dataset of purine measurements from
stroke patients and controls to date. Our study with
SMARTCap demonstrates that the purines are indeed elevated
in stroke patients relative to controls and that the level of
purines correlates with the volume of affected brain tissue.
To gain an idea of diagnostic performance, we performed a
ROC analysis (Fig. 8) on the data to evaluate the discrimina-
tory power of the SMARTCap test. For strokes versus con-
trols, the area under the curve (AUC) was 0.65 (95% confi-
dence interval 0.56 to 0.75), while for strokes versus mimics,
the AUC was 0.68 (95% confidence interval 0.51 to 0.86).
Clearly, this diagnostic performance is inadequate for clinical
use. Nevertheless, given the technical limitations of
SMARTCap and its use in the clinical setting, this perfor-
mance is promising.
Our proof of principle study establishes that purines are
released into the blood of stroke patients. Furthermore, this
study confirms the finding of a related study in patients un-
dergoing carotid artery surgery [31] that purines are produced
within minutes of the onset of ischaemia. This could make
purines better biomarkers for acute ischaemia than proteomic
biomarkers, which require hours to become apparent. The
purine levels detected in blood correlate with the volume of
affected brain tissue determined by medical imaging. This in
turn suggests that an early purine measurement has potential
not only to help in identifying stroke patients but also to give
information as to its severity that is independent of clinical
assessment scales such as the NIHSS. Nevertheless, the pres-
ent study is limited by the use of imperfect point-of-care mea-
surement technology. As a result, the level of variance in the
data precludes use as a diagnostic tool at this stage. However,
our data warrant the development of better devices less prone
to measurement error with better usability in a clinical and
prehospital setting. The use of such devices will enable a more
realistic evaluation of the diagnostic potential of purine release
into blood for stroke that can be made.
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